Tetraphase Pharmaceuticals, Inc. (TTPH) to Release Quarterly Earnings on Wednesday
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will be announcing its earnings results after the market closes on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.76) per share for the quarter.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.19. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.46 million. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The business’s revenue was down 24.5% compared to the same quarter last year. During the same period last year, the company earned ($0.46) EPS. On average, analysts expect Tetraphase Pharmaceuticals to post $-2.74 EPS for the current fiscal year and $-2.18 EPS for the next fiscal year.
Tetraphase Pharmaceuticals, Inc. (TTPH) opened at 6.90 on Wednesday. The company’s market cap is $261.90 million. Tetraphase Pharmaceuticals, Inc. has a 12 month low of $3.11 and a 12 month high of $9.93. The firm has a 50-day moving average price of $7.47 and a 200 day moving average price of $6.81.
A number of equities research analysts have commented on TTPH shares. BMO Capital Markets restated a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. HC Wainwright started coverage on Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $8.45.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.